Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | F7 | P08709 | 3/20 | 0.38 |
| ▸ | F3 | P13726 | 3/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18651076 | 0.94 | ALDH1A1 (0.46) | ALDH1A1F7F3CYP19A1MAPT | |
| SCHEMBL18651103 | 0.92 | PPARA (0.31) | ALDH1A1CYP19A1MAPTOXER1PPARG | |
| SCHEMBL18651081 | 0.86 | ALDH1A1 (0.39) | ALDH1A1F7F3CYP19A1MAPT | |
| SCHEMBL3320012 | 0.75 | ALDH1A1 (0.54) | ALDH1A1F7F3CYP19A1MAPT | |
| SCHEMBL5054215 | 0.75 | ALDH1A1 (0.54) | ALDH1A1F7F3CYP19A1MAPT | |
| SCHEMBL5054346 | 0.75 | ALDH1A1 (0.54) | ALDH1A1F7F3CYP19A1MAPT | |
| SCHEMBL8834834 | 0.72 | ALDH1A1 (0.50) | ALDH1A1F7F3CYP19A1MAPT | |
| SCHEMBL8834831 | 0.72 | ALDH1A1 (0.50) | ALDH1A1F7F3CYP19A1MAPT | |
| SCHEMBL18656463 | 0.72 | ALDH1A1 (0.50) | ALDH1A1F7F3CYP19A1MAPT | |
| SCHEMBL987638 | 0.72 | FFAR1 (0.31) | ALDH1A1CYP19A1MAPTOXER1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230058971-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | Graybug Vision, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20230056284-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | Graybug Vision, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20200230246-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | Graybug Vision, Inc. (US) | 2020-07-23 | — | — | US | disclosed |
| US-9956302-B2 | Compounds and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20180110864-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180110864-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180104350-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180064823-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20180064823-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20180036416-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180036416-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180028673-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180028673-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028673-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | ALDH1A1 1010/4885F7 2909/4885F3 3528/4885 |
| US-20180064823-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | ALDH1A1 1010/4885F7 2909/4885F3 3528/4885 |
| US-20180036416-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | ALDH1A1 1010/4885F7 2909/4885F3 3528/4885 |
| US-20230058971-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | CHMP4B, EXOSC9, EXOSC5 | ALDH1A1 2063/4885F7 215/4885F3 2293/4885 |
| US-20200230246-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | CHMP4B, EXOSC9, EXOSC5 | ALDH1A1 2063/4885F7 215/4885F3 2293/4885 |
| US-20180110864-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | ALDH1A1 1010/4885F7 2909/4885F3 3528/4885 |
| US-20180104350-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | ALDH1A1 1010/4885F7 2909/4885F3 3528/4885 |
| US-20230056284-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | CHMP4B, EXOSC9, EXOSC5 | ALDH1A1 2063/4885F7 215/4885F3 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.